Scarica l'app Stockscreener
3.62
1.40%
0.05
Precedente Chiudi:
$3.57
Aprire:
$3.55
Volume 24 ore:
727.14K
Relative Volume:
0.64
Capitalizzazione di mercato:
$1.23B
Reddito:
$787.89M
Utile/perdita netta:
$20.56M
Rapporto P/E:
61.88
EPS:
0.0585
Flusso di cassa netto:
$96.54M
1 W Prestazione:
+7.74%
1M Prestazione:
+9.04%
6M Prestazione:
+57.39%
1 anno Prestazione:
-6.22%
Intervallo 1D:
$0.00
$0.00
Intervallo di 1 settimana:
$3.35
$3.64
Portata 52W:
$1.77
$4.05
Goodrx Holdings Inc Stock (GDRX) Company Profile
Nome
Goodrx Holdings Inc
Settore
Industria
Telefono
(855) 268-2822
Indirizzo
2701 OLYMPIC BOULEVARD, SANTA MONICA
Compare GDRX vs VEEV, BTSG, TEM, HNGE, HQY
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
3.62 | 1.23B | 787.89M | 20.56M | 96.54M | 0.0585 |
VEEV
Veeva Systems Inc
|
322.55 | 52.22B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
60.86 | 12.04B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
63.81 | 11.59B | 1.36B | -302.91M | -219.93M | -1.7182 |
HNGE
Hinge Health Inc
|
109.93 | 8.87B | 646.34M | -512.40M | 202.76M | -6.6871 |
HQY
Healthequity Inc
|
100.97 | 8.35B | 1.34B | 230.70M | 440.96M | 2.6695 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-27 | Downgrade | JP Morgan | Overweight → Neutral |
| 2026-01-22 | Downgrade | Jefferies | Buy → Hold |
| 2025-12-09 | Iniziato | Barclays | Underweight |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Iniziato | Mizuho | Neutral |
| 2024-08-09 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Aggiornamento | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Iniziato | Leerink Partners | Outperform |
| 2024-01-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2023-08-10 | Aggiornamento | DA Davidson | Neutral → Buy |
| 2023-07-31 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Iniziato | Citigroup | Buy |
| 2022-11-04 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-08-12 | Iniziato | DA Davidson | Neutral |
| 2022-06-10 | Downgrade | Goldman | Buy → Neutral |
| 2022-06-06 | Ripresa | BofA Securities | Buy |
| 2022-06-01 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Iniziato | Wells Fargo | Equal Weight |
| 2022-04-07 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Neutral |
| 2022-03-15 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Reiterato | Barclays | Overweight |
| 2022-03-01 | Reiterato | BofA Securities | Neutral |
| 2022-03-01 | Downgrade | Cowen | Outperform → Market Perform |
| 2022-03-01 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Reiterato | Evercore ISI | Outperform |
| 2022-03-01 | Reiterato | Goldman | Buy |
| 2022-03-01 | Reiterato | JP Morgan | Underweight |
| 2022-03-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-03-01 | Reiterato | SVB Leerink | Outperform |
| 2022-01-07 | Iniziato | Goldman | Buy |
| 2021-12-21 | Iniziato | Stephens | Overweight |
| 2021-12-02 | Iniziato | Jefferies | Buy |
| 2021-08-31 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Iniziato | Robert W. Baird | Neutral |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-01-25 | Iniziato | Guggenheim | Buy |
| 2020-11-19 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Iniziato | Barclays | Equal Weight |
| 2020-10-19 | Iniziato | BofA Securities | Neutral |
| 2020-10-19 | Iniziato | Citigroup | Buy |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-10-19 | Iniziato | Credit Suisse | Outperform |
| 2020-10-19 | Iniziato | Deutsche Bank | Hold |
| 2020-10-19 | Iniziato | Goldman | Neutral |
| 2020-10-19 | Iniziato | JP Morgan | Neutral |
| 2020-10-19 | Iniziato | Morgan Stanley | Overweight |
| 2020-10-19 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Iniziato | SVB Leerink | Outperform |
| 2020-10-19 | Iniziato | UBS | Buy |
Mostra tutto
Goodrx Holdings Inc Borsa (GDRX) Ultime notizie
Upwork Inc. (UPWK) Stock Price & News - Syfe
Form 4 Goodrx Holdings Inc: Thomas (Tc) Chan (Chief Accounting Officer) For: 15 October By Investing.com - Investing.com South Africa
Form 4 Goodrx Holdings Inc: Justin Fengler (Officer) For: 15 October - Investing.com Canada
Form 4 Goodrx Holdings Inc: Justin Fengler (Officer) For: 15 October - Investing.com Nigeria
Form 4 Goodrx Holdings Inc: Wendy Lynn Barnes (Director, Officer) For: 15 October - Investing.com India
Form 4 Goodrx Holdings Inc: Wendy Lynn Barnes (Director, Officer) For: 15 October - Investing.com Nigeria
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of GoodRx Holdings, Inc. (GDRX) Investors - Lelezard
GoodRx Holdings (NasdaqGS:GDRX) Stock Forecast & Analyst Predictions - Simply Wall Street
GoodRx CFO Justin Fengler Reports RSU Vesting and Share Withholding on September 15, 2026 - Kalkine Media
GoodRx CAO Thomas Chan Reports RSU Vesting and Tax-Related Share Withholding on September 15, 2026 - Kalkine Media
GoodRx (GDRX) exec converts RSUs and withholds shares for taxes - Stock Titan
GoodRX’s $32 Million Data-Sharing Settlement Wins Initial Nod - Bloomberg Law News
AIAI Stock Price, Quote & News - Syfe
TaskUs, Inc. Class A (TASK) Stock Price & News - Syfe
InvestingPro Fair Value delivers 64% return on GoodRx in 5 months By Investing.com - Investing.com Australia
InvestingPro Fair Value delivers 64% return on GoodRx in 5 months By Investing.com - investing.com
GoodRx offers health subscription for families, to launch as employee benefit in 2027 - reuters.com
GDRX Looks 34.8% Undervalued on GF Value™ - GuruFocus
One plan covers kids, adults and pets. GoodRx's new membership costs $24.99 a month. - Stock Titan
Promising Penny Stocks To Consider In August 2026 - simplywall.st
Gloo Holdings, Inc. Class A (GLOO) Stock Price & News - Syfe
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and GoodRx Holdings (GDRX) - The Globe and Mail
GoodRx (NASDAQ:GDRX) 10% owner Francisco Partners sells $5.48m in stock - Investing.com Nigeria
GoodRx (NASDAQ:GDRX) 10% owner Francisco Partners sells $5.48m in stock - Investing.com India
Major GoodRx (NASDAQ: GDRX) holder reshapes stake via conversion and sale - Stock Titan
GoodRx (NASDAQ:GDRX) 10% owner Francisco Partners sells $5.48m in stock - Investing.com
GoodRx Stock (GDRX) Opinions on TrumpRx Partnership - Moomoo
GoodRx Stock (GDRX) Opinions on TrumpRx Partnership - Quiver Quantitative
GoodRx (GDRX) Results Breakdown: The Available Scorecard Is Mostly Near Expectations in the Current Update; Share Move: Shares Close 3.09% Lower in Latest TradingROE Trend Analysis - vinanet.vn
GoodRx (GDRX) Results Breakdown: The Available Scorecard Is Mostly Near Expectations in the Current Update; Share Move: Shares Close 3.09% Lower in Latest TradingProfit Announcement - vinanet.vn
GoodRx 10% owner Francisco Partners sells $4.2m in shares By Investing.com - Investing.com Australia
GoodRx 10% owner Francisco Partners sells $4.2m in shares By Investing.com - Investing.com India
GDRX Maintains Underweight Rating -- Price Target Raised to $4.0 - GuruFocus
Q2 2026 GoodRx Holdings, Inc. Earnings Call Transcript - GuruFocus
GoodRx 10% owner Francisco Partners sells $4.2m in shares - Investing.com
GoodRx(GDRX.US) 10% Shareholder Sells US$4.2 Million in Common Stock - Moomoo
Justin Fengler Net Worth (2026) - GuruFocus
Big GoodRx (NASDAQ: GDRX) backer prepares share sale - Stock Titan
Technology Crossover Management X Ltd. Buys Shares of 1,653,566 GoodRx Holdings, Inc. $GDRX - MarketBeat
GoodRx (GDRX) Results at a Glance: The Available Figures Are Largely Near Expectations at the Close; Stock Move - vinanet.vn
GoodRx (GDRX) Results at a Glance: The Available Figures Are Largely Near Expectations at the Close; Stock Move - vinanet.vn
GoodRx (GDRX) Results at a Glance: The Available Figures Are Largely Near Expectations at the Close; Stock Move: Shares Move Lower 1.88% in Latest TradingShare Repurchase Impact - siam.in
GoodRx Holdings Inc (GDRX) (Q2 2026) Earnings Call Highlights: R - GuruFocus
GoodRx (NASDAQ:GDRX) Rating Increased to Buy at Wall Street Zen - MarketBeat
Reflecting On Healthcare Technology Stocks’ Q2 Earnings: GoodRx (NASDAQ:GDRX) - Yahoo Finance
GoodRx Holdings, Inc. (NASDAQ:GDRX) Receives Average Rating of "Hold" from Brokerages - MarketBeat
GDRX Maintained by UBS -- Price Target Raised to $3.75 - GuruFocus
GoodRx (GDRX) Stock Looks Overvalued On Its Earnings Outlook - Yahoo Finance
GoodRx Holdings (GDRX) Could Be 13% Overvalued After Q2 Earnings and Guidance Raise - Yahoo Finance
GoodRx (GDRX) Stock Trades At A Premium On Earnings Despite Weak Returns - webull.com
Goodrx Holdings Inc Azioni (GDRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Goodrx Holdings Inc Azioni (GDRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| FRANCISCO PARTNERS IV, L.P. | 10% Owner |
Aug 25 '26 |
Sale |
3.44 |
127,273 |
438,443 |
643,466 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner |
Aug 24 '26 |
Sale |
3.46 |
143,594 |
497,122 |
706,649 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner |
Aug 21 '26 |
Sale |
3.50 |
274,717 |
960,630 |
777,213 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner |
Aug 20 '26 |
Sale |
3.52 |
447,259 |
1,574,575 |
913,592 |
| Francisco Partners GP IV, L.P. | 10% Owner |
Aug 19 '26 |
Proposed Sale |
3.72 |
2,760,995 |
10,270,901 |
0 |
| FRANCISCO PARTNERS IV, L.P. | 10% Owner |
Aug 19 '26 |
Sale |
3.53 |
471,975 |
1,666,025 |
1,127,436 |
| IAN THORNTON CLARK | Director |
May 13 '26 |
Proposed Sale |
2.59 |
43,100 |
111,620 |
0 |
| REY-GIRAUD AGNES | Director |
Mar 12 '26 |
Option Exercise |
0.47 |
192,185 |
90,327 |
277,633 |
| Spectrum Equity VII, L.P. | 10% Owner |
Oct 15 '25 |
Sale |
4.00 |
23,771 |
95,103 |
0 |
| Spectrum VII Co-Investment Fun | Affiliate |
Oct 15 '25 |
Proposed Sale |
4.02 |
8,569 |
34,447 |
0 |
3.46%
0.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):